당뇨병 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Antidiabetics Market size is expected to reach USD 214.06 Billion in 2034 from USD 98.23 Billion (2025) growing at a CAGR of 9.04% during 2026-2034.

The global antidiabetics market is experiencing significant growth due to the rising prevalence of diabetes worldwide. Factors such as sedentary lifestyles, unhealthy diets, and increasing obesity rates are contributing to the growing number of diabetic patients. This has led to a higher demand for effective medications to manage blood glucose levels and prevent complications.

Major drivers include advancements in drug development, including innovative insulin therapies and oral antidiabetic drugs. The increasing adoption of combination therapies and personalized treatment approaches is also supporting market expansion. Additionally, growing awareness about diabetes management and government initiatives to improve healthcare access are boosting demand.

Looking ahead, the market is expected to benefit from continuous research and development, leading to more effective and convenient treatment options. The integration of digital health technologies, such as glucose monitoring devices and mobile health applications, will further enhance patient outcomes. As the global burden of diabetes continues to rise, the antidiabetics market is set for sustained growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Insulin
• Rapid Acting
• Long Acting
• Premixed Insulin
• Short Acting

By Drug Class

• Biguanides
• GLP-Agonists
• Thiazolidinediones
• Sulphonylureas
• SGLT-2
• Alpha-Glucosidase Inhibitors
• DPP-4 Inhibitors
• Meglitinides

By Patient Population

• Pediatric
• Adults
• Geriatric

By Route of Administration

• Oral
• Infusion
• Intravenous
• Insulin Pumps
• Insulin Pen/Syringes

COMPANIES PROFILED

• Eli Lilly and Company, , Boehringer Ingelheim, BristolMyers Squibb Company, Pfizer Inc, Halozyme Therapeutics, AstraZeneca Plc, Bayer AG, Johnson Johnson Services Inc, Sanofi SA, Oramed Pharmaceuticals, Novo Nordisk, Merck Co Inc, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIDIABETICS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Insulin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Rapid Acting Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Long Acting Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Premixed Insulin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Short Acting Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIDIABETICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Biguanides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. GLP-Agonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Thiazolidinediones Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Sulphonylureas Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. SGLT-2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Alpha-Glucosidase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. DPP-4 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Meglitinides Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIDIABETICS MARKET: BY PATIENT POPULATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Patient Population
• 6.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Geriatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIDIABETICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Infusion Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Insulin Pumps Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Insulin Pen/Syringes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTIDIABETICS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Drug Class
  • 8.2.3 By Patient Population
  • 8.2.4 By Route Of Administration
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Drug Class
  • 8.3.3 By Patient Population
  • 8.3.4 By Route Of Administration
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Drug Class
  • 8.4.3 By Patient Population
  • 8.4.4 By Route Of Administration
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Drug Class
  • 8.5.3 By Patient Population
  • 8.5.4 By Route Of Administration
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Drug Class
  • 8.6.3 By Patient Population
  • 8.6.4 By Route Of Administration
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ANTIDIABETICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Boehringer Ingelheim
  • 10.2.2 Bristol-Myers Squibb Company
  • 10.2.3 Pfizer Inc
  • 10.2.4 Halozyme Therapeutics
  • 10.2.5 AstraZeneca Plc
  • 10.2.6 Bayer AG
  • 10.2.7 Johnson & Johnson Services Inc
  • 10.2.8 Sanofi S.A
  • 10.2.9 Oramed Pharmaceuticals
  • 10.2.10 Novo Nordisk
  • 10.2.11 Merck & Co. Inc
  • 10.2.12 Novartis AG